Viridian Therapeutics is a biopharmaceutical company. Co. has built relevant capabilities in monoclonal antibody discovery and engineering, biologics manufacturing, and nonclinical and clinical development for thyroid eye disease (TED) and other undisclosed target indications in rare and autoimmune diseases. Co. is developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that are being developed for intravenous or subcutaneous administration to treat patients who suffer from TED. Co.'s primary program, VRDN-001, is a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor intravenously administered for the treatment for TED. We show 14 historical shares outstanding datapoints in our VRDN shares outstanding history coverage, used to compute VRDN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VRDN market cap history over the course of time is important for investors
interested in comparing VRDN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VRDN versus a peer is one thing; comparing
VRDN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VRDN can fluctuate over the course of history.
With this page we aim to empower investors researching VRDN by allowing them to research the VRDN market cap history. |
Free VRDN Email Alerts:
Video: The Importance of Market Cap
